Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 18;51(1):83.
doi: 10.1186/s13052-025-01919-7.

Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: a single-center experience and assessment of quality of life

Wen Zhang #  1 , Yonglan Huang #  2 , Xueying Su  1 , Xiaoyuan Zhao  1 , Huiying Sheng  1 , Cuili Liang  1 , Minyan Jiang  1 , Chunhua Zeng  1 , Yanna Cai  1 , Yunting Lin  1 , Yongxian Shao  1 , Sha Liu  3 , Hua Jiang  4 , Li Liu  5
Affiliations

Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: a single-center experience and assessment of quality of life

Wen Zhang et al. Ital J Pediatr. .

Abstract

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) has proven to be a viable treatment option for patients with mucopolysaccharidoses (MPS). We investigate the efficacy and improvements in the quality of life of HSCT in pediatric patients with MPS.

Methods: A retrospective analysis of transplantation data from 46 cases of MPS from a single institution in China was conducted.

Results: The cohort of 46 patients included 9 cases of MPS I, 16 cases of MPS II, 15 cases of MPS IVA and 6 cases of MPS VI. The median age at diagnosis was 2.59 years. The median age at transplantation was 3.80 years. The median follow-up time was 3.1 years (range, 0.8-8.1 years) and 43 patients were alive. The incidence of grades II to IV aGVHD was 17.4%, wherein the incidence of grades III and IV aGVHD was 4.3%. The incidence of moderate-to-severe cGVHD was 6.5%. GAGs urinary excretion decreased and enzyme activity levels reached normal. After HSCT, multiple bone dysplasia, upper-airway obstruction and recurrent otitis media were significantly improved; vision, corneal clouding, cardiovascular disease, hepatosplenomegaly and hydrocephalus were improved or remained stable; neurological symptoms were improved or remained stable in most patients but progressed in others; the patients with MPS IH/S and MPS II reached nearly normal growth rate of height and weight. Meanwhile, the patients with MPS IH, MPS IVA and MPS VI remained poor growth after HSCT. The Activities of Daily Living (ADL) scores were improved in most patients with MPS. ADL scores in patients with severe phenotypes were lower than health control subjects and patients with attenuated phenotypes.

Conclusions: HSCT is a good therapeutic option for MPS and improves the quality of life of patients. MPS patients with attenuated phenotypes provide a better outcome in ADL after HSCT.

Keywords: Allogeneic hematopoietic stem cell transplantation; Mucopolysaccharidosis; Outcomes; Quality of life.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: The study was approved by the Institutional Review Board of Guangzhou Women and Children’s Medical Center and all methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from the legal guardians of all the participants in the study. Consent for publication: Institutional consent form has been used to obtain the consent to publication from children’s parents or legal guardian. Competing interests: The authors declare that they have no competing interests. The study was carried out according to the amended Declaration of Helsinki.

Figures

Fig. 1
Fig. 1
Urinary glycosaminoglycans: creatinine (GAGs: Cr) ratio recorded before and after HSCT
Fig. 2
Fig. 2
ADL score for patients with MPS beforea and afterb HSCT
Fig. 3
Fig. 3
ADL scores in patients with MPS with or without HSCT. The graph shows the mean of the scores for each item. All subjects are over 5 years of age
See this image and copyright information in PMC

References

    1. .Çelik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of mucopolysaccharidoses update. Diagnostics (Basel). 2021;11(2):273. - PMC - PubMed
    1. Verheyen S, Blatterer J, Speicher MR, Bhavani GS, Boons GJ, Ilse MB, et al. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J Med Genet. 2022;59(10):957–64. - PMC - PubMed
    1. Vasilev F, Sukhomyasova A, Otomo T. Mucopolysaccharidosis-Plus syndrome. Int J Mol Sci. 2020;21(2):421. - PMC - PubMed
    1. Chen HH, Sawamoto K, Mason RW, Kobayashi H, Yamaguchi S, Suzuki Y, et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet. 2019;64(11):1153–71. - PubMed
    1. Sawamoto K, Stapleton M, Alméciga-Díaz CJ, Espejo-Mojica AJ, Losada JC, Suarez DA, et al. Therapeutic options for mucopolysaccharidoses: current and emerging treatments. Drugs. 2019;79(10):1103–34. - PubMed

LinkOut - more resources